Bavarian Nordic Announces First Subject Dosed with MVA-BN®

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bavarian Nordic Announces First Subject Dosed with MVA-BN® Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines

* First human trial investigating MVA-BN® Filo as an Ebola vaccine * MVA-BN Filo is being investigated as a booster in an ongoing Phase study 1 of the cAd3-EBO Z vaccine being developed by GSK and the U.S. National Institutes of Health (NIH) KVISTGAARD, Denmark, December 4, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the first subject has been dosed with MVA-BN Filo in a Phase 1 safety and immunogenicity trial, evaluating a heterologous prime-boost regimen of Ebola candidate vaccines. The trial, sponsored by the University of Oxford, is assessing the monovalent cAd3-EBO Z vaccine co-developed by GSK and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and Bavarian Nordic's multivalent MVA- ¬BN Filo vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus. Recent preclinical research has shown that by employing an MVA-based booster dose, the vaccine may offer a more robust and durable immune response. The investigators hope to be able to replicate these findings in clinical studies and have therefore chosen to include Bavarian Nordic's MVA-BN Filo vaccine in the study for a heterologous boost. The study is enrolling 60 healthy adults in three cohorts receiving different doses of the cAd3-EBO Z vaccine. Half of the subjects in each cohort will furthermore receive a booster dose of the MVA-BN Filo vaccine. Primary objective is the assessment of safety and tolerability; secondary objective is the assessment of cellular and humoral immune responses. Preliminary results from the study are anticipated in the first half of 2015. More information on the trial can be found at http://clinicaltrials.gov/ct2/show/NCT02240875. Both the cAd3-EBO Z vaccine and the MVA-BN Filo vaccine have been developed in collaboration with NIAID. In partnership with Bavarian Nordic and Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, NIAID furthermore investigated a prime-boost regimen of Bavarian Nordic's MVA-BN Filo and Janssen's AdVac® technology. Based on promising preclinical results, Bavarian Nordic and Janssen recently entered into a collaboration to develop and manufacture large quantities of this vaccine regimen, which is planned to enter clinical trials shortly. "In support of the various clinical trials currently underway to fast-track the development of urgently needed vaccines against Ebola, we are pleased that these studies may confirm the role of a heterologous prime boost regimen incorporating the MVA-BN vaccine platform technology," said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. "We are also making progress in our collaboration with Janssen as part of their commitment to accelerate and expand the production of its Ebola vaccine regimen. Manufacturing of our MVA-BN Filo vaccine is well underway and the first trial in humans of this prime-boost vaccine regimen will soon open for enrollment." Contacts Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43 Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654 About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.  For more information, visit www.bavarian-nordic.com. About MVA-BN® MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic. MVA-BN is a robust and adaptable platform suitable for addressing a wide variety of infectious diseases, including biological threats. In addition to developing MVA-BN as a safer smallpox vaccine (approved in the EU and Canada) essential to protecting the immune-compromised population, Bavarian Nordic has conducted more than a dozen preclinical and clinical studies of recombinant MVA-BN-based vaccines.  More than 7,500 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. [HUG#1877031]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 175

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 34

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 16

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 211

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 0

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 120

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 0

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

A.B. Data Appoints Steve Straub as New Operations VP

Updated Category News Views 542

A.B. Data Appoints Steve Straub as New Operations VP A.B. Data, a prominent name in class action notice and claims administration, has elevated Steve Straub to the role of Vice President of Operations. Having served as the Senior Director of Operations since 2023, Steve brings a wealth of experience that will further strengthen the company’s operations. Strategic...

Continue Reading
Conexon Connect Expands Fiber Network for Rural Internet Access

Updated Category News Views 170

Conexon Connect's Milestone Achievement Conexon Connect has successfully completed a transformative fiber-to-the-home (FTTH) project, expanding high-speed internet access to over 12,000 members of rural electric cooperatives. This expansive network marks a significant achievement in bridging the digital divide, particularly for underserved communities. Partnerships...

Continue Reading
Xiaomi MIX Flip 2 Unveils TCL CSOT's Cutting-Edge Displays

Updated Category News Views 349

TCL CSOT Powers the Xiaomi MIX Flip 2's Display Experience TCL CSOT is making waves in the tech world by providing state-of-the-art displays for the Xiaomi MIX Flip 2. This new foldable smartphone marks a significant shift in user experiences, aligning perfectly with the growing demand for portable, high-performance devices. During a recent launch event showcasing...

Continue Reading
Immunic Showcases Promising Results for Vidofludimus Calcium

Updated Category News Views 106

Immunic Highlights Key Findings from CALLIPER Trial Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company specializing in innovative oral therapies for neurologic and gastrointestinal conditions, recently presented significant data from its Phase 2 CALLIPER trial. This trial evaluates its cornerstone therapy, vidofludimus calcium (IMU-838), aimed at treating...

Continue Reading
Amrop Expands Global Reach with New Office in Colombia

Updated Category News Views 153

Amrop Expands With a New Office in Colombia Amrop, a distinguished global executive search and leadership consulting firm, has recently announced the establishment of a new office in Colombia. This expansion marks a significant milestone for Amrop as they enhance their service offerings in Latin America. Introducing Amrop Colombia Amrop Colombia emerges from the merger...

Continue Reading